Skip to main content
Premium Trial:

Request an Annual Quote

Celera Genomics Changes Name to Celera

NEW YORK (GenomeWeb News) — Celera Genomics has been renamed Celera, according to a Securities and Exchange Commission filing late last month.
The Applera unit will be formally called Celera Group. It had been known as Celera Genomics Group.
 
Shareholders approved the name change at the firm’s annual investor conference on Oct. 19. It became effective Dec. 1.
 
Celera will continue to trade on the New York Stock Exchange under the “CRA” ticker symbol. Stockholders will not be required to change out their share certificates.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.